Stock 0GY1 SWEDISH ORPHAN BIOVITRUM
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News SWEDISH ORPHAN BIOVITRUM London S.E.

Equities

0GY1

End-of-day quote London S.E.
Other stock markets
- SEK - Intraday chart for SWEDISH ORPHAN BIOVITRUM
06-19 Sobi Wins EU Approval for Hemophilia A Drug Altuvoct MT
06-19 European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sobi Wins EU Approval for Hemophilia A Drug Altuvoct
MT
European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A
CI
Swedish Orphan Biovitrum : European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A
PU
Swedish Orphan Biovitrum : Sobi to present new haemophilia data at ISTH 2024
PU
Swedish Orphan Biovitrum : Sobi to present new data across its haematology portfolio at the 2024 EHA congress
PU
BerGenBio ASA Enter into A Clinical Trial Agreement with the Mays Cancer Center At the University of Texas Health Science Center At San Antonio and Swedish Orphan Biovitrum AB
CI
Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
GL
Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment
DJ
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome
GL
Bulletin from Sobi's Annual General Meeting (AGM)
AQ
Swedish Orphan Biovitrum AB Elects Zlatko Rihter as New Board Member
CI
Sobi Finalizes Inaugural SEK3 Billion Bond Issue
MT
Sobi Secures Additional EU Indication for Rare Blood Disorder Therapy
MT
Sobi has completed SEK 3 billion senior bond issue
AQ
Aspaveli® (pegcetacoplan) approved in Europe for use among treatment naïve adult patients with PNH
AQ
Sobi Wins EU Regulatory Panel's Positive Opinion for Hemophilia A Drug
MT
Sobi Receives Positive CHMP Opinion Recommending Approval of efanesoctocog alfa for Once-Weekly Treatment of Haemophilia A
CI
Sobi's SEK10 Billion Note Program Gets Regulatory Nod in Sweden
MT
Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
AQ
Sobi establishes MTN programme with a framework amount of SEK 10 billion, publishes a base prospectus
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SOBI Stock
  4. 0GY1 Stock
  5. News SWEDISH ORPHAN BIOVITRUM